Demonstrates synergic photo-activated chemotherapy and photodynamic therapy using nanohybrids in an FDA-approved framework, indicating potential advancements in cancer treatment.
Prussian blue nanoparticles (PBNPs), an FDA-approved iron hexacyanoferrate framework, have emerged as multifunctional nanoplatforms for phototherapy owing to their biocompatibility, photostability, and strong red-to-NIR absorption. Building upon these advantages, we...
No takes yet. Share an insight, caveat, or question.
Bhowmik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: